Skip to main content
Top
Published in: Virchows Archiv 5/2005

01-11-2005 | Original Article

Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas

Authors: Yu-Zhen Feng, Tanri Shiozawa, Akiko Horiuchi, Hsien-Chang Shih, Tsutomu Miyamoto, Hiroyasu Kashima, Akihisa Suzuki, Toshio Nikaido, Ikuo Konishi

Published in: Virchows Archiv | Issue 5/2005

Login to get access

Abstract

To further elucidate the significance of p53 mutation in endometrial carcinoma, we investigated it in endometrioid-type endometrial carcinomas showing intratumoral heterogeneous p53 expression. In addition, we also examined the correlation of p53 mutation and cyclin A expression, because we previously reported a topological correlation between the expression of p53 and cyclin A. The p53 mutation in exons 5–8 in 54 cases of endometrial carcinoma showing immunohistochemical expression of p53 was examined using microdissected tissue DNAs. Of the 54 p53-positive endometrial carcinomas, 23 (43%) had p53 mutation with a tendency in histologically higher grade tumors. Ten of the 54 showed a heterogeneous p53 expression, and in 9 of the 10 cases, p53 mutation was present only in p53-positive sites, which were often found in histologically less differentiated areas with elevated Ki-67 in the same tumor. Cyclin A expression was topologically observed in p53-positive areas; however, it was noted in both tumors with (12/23, 52%) and without (18/31, 58%) p53 mutation. These results suggest that p53 mutation is a late event and plays an important role in the acquisition of malignant potentials in endometrioid-type endometrial adenocarcinomas. Unexpectedly, accumulation of the p53 protein itself may be important in cyclin A overexpression.
Literature
1.
go back to reference Ambros RA, Ross JS, Kallakury BV, Malfetano J, Kim Y, Hwang J, Breese K, Figge J (1995) p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis. Mod Path 8:441–445 Ambros RA, Ross JS, Kallakury BV, Malfetano J, Kim Y, Hwang J, Breese K, Figge J (1995) p53 gene status in endometrial carcinomas showing diffuse positivity for p53 protein by immunohistochemical analysis. Mod Path 8:441–445
2.
go back to reference Barakat RR, Grisby PW, Sabbatini P (2000) Corpus: epithelial tumors. In: Hoskins WJ, Perez CA, Young RC (eds) Principles and practice of gynecologic oncology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 919–959 Barakat RR, Grisby PW, Sabbatini P (2000) Corpus: epithelial tumors. In: Hoskins WJ, Perez CA, Young RC (eds) Principles and practice of gynecologic oncology, 3rd edn. Lippincott Williams & Wilkins, Philadelphia, pp 919–959
4.
go back to reference Crompton NE, Saydan N (1999) Control of the cell cycle. J Neuro-Oncol 22:255–259CrossRef Crompton NE, Saydan N (1999) Control of the cell cycle. J Neuro-Oncol 22:255–259CrossRef
5.
go back to reference Dictor M, Ehinger M, Mertens F, Akervall J, Wennerberg J (1999) Abnormal cell cycle regulation in malignancy. Am J Clin Pathol 112:40–52 Dictor M, Ehinger M, Mertens F, Akervall J, Wennerberg J (1999) Abnormal cell cycle regulation in malignancy. Am J Clin Pathol 112:40–52
7.
go back to reference Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299CrossRefPubMed Haupt Y, Maya R, Kazaz A, Oren M (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299CrossRefPubMed
8.
go back to reference Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53PubMedCrossRef Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253:49–53PubMedCrossRef
9.
go back to reference Ito K, Sasano H, Matsunaga G, Sato S, Yajima A, Nasim S, Garret CT (1997) Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 183:318–324PubMedCrossRef Ito K, Sasano H, Matsunaga G, Sato S, Yajima A, Nasim S, Garret CT (1997) Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. J Pathol 183:318–324PubMedCrossRef
10.
go back to reference Kihana T, Hamada K, Inoue Y, Yano N, Iketani H, Murao S, Ukita M, Matsuura S (1995) Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. Cancer 76:72–78PubMedCrossRef Kihana T, Hamada K, Inoue Y, Yano N, Iketani H, Murao S, Ukita M, Matsuura S (1995) Mutation and allelic loss of the p53 gene in endometrial carcinoma. Incidence and outcome in 92 surgical patients. Cancer 76:72–78PubMedCrossRef
11.
go back to reference Koga T, Hashimoto S, Sugio K, Yoshino I, Nakagawa K, Yonemitsu Y, Sugimachi K, Sueishi K (2001) Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation. Int J Cancer 95:232–239CrossRefPubMed Koga T, Hashimoto S, Sugio K, Yoshino I, Nakagawa K, Yonemitsu Y, Sugimachi K, Sueishi K (2001) Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinoma correlates with MDM2 protein expression, rather than with P53 gene mutation. Int J Cancer 95:232–239CrossRefPubMed
12.
go back to reference Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC Jr, Marks JR (1992) Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52:1622–1627PubMed Kohler MF, Berchuck A, Davidoff AM, Humphrey PA, Dodge RK, Iglehart JD, Soper JT, Clarke-Pearson DL, Bast RC Jr, Marks JR (1992) Overexpression and mutation of p53 in endometrial carcinoma. Cancer Res 52:1622–1627PubMed
13.
go back to reference Koshiyama M, Konishi I, Fujii S (1998) Pathology, hormonal aspects, and molecular genetics of the two types of endometrial cancer. Cancer J 11:277–283 Koshiyama M, Konishi I, Fujii S (1998) Pathology, hormonal aspects, and molecular genetics of the two types of endometrial cancer. Cancer J 11:277–283
14.
15.
go back to reference Ronnett BM, Zaino RJ, Ellenson H, Kurman RJ (2002) Endometrial carcinoma. In: Kurmann RJ (ed) Blaustein's pathology of the female genital tract, 5th edn. Springer, Berlin Heidelberg New York, pp 501–559 Ronnett BM, Zaino RJ, Ellenson H, Kurman RJ (2002) Endometrial carcinoma. In: Kurmann RJ (ed) Blaustein's pathology of the female genital tract, 5th edn. Springer, Berlin Heidelberg New York, pp 501–559
16.
go back to reference Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444:213–223CrossRefPubMed Lax SF (2004) Molecular genetic pathways in various types of endometrial carcinoma: from a phenotypical to a molecular-based classification. Virchows Arch 444:213–223CrossRefPubMed
17.
go back to reference Li SF, Shiozawa T, Nakayama K, Nikaido T, Fujii S (1996) Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Cancer 77:321–329CrossRefPubMed Li SF, Shiozawa T, Nakayama K, Nikaido T, Fujii S (1996) Stepwise abnormality of sex steroid hormone receptors, tumor suppressor gene products (p53 and Rb), and cyclin E in uterine endometrioid carcinoma. Cancer 77:321–329CrossRefPubMed
18.
go back to reference Luciani MG, Hutchins JR, Zheleva D, Hupp TR (2000) The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol 300:503–518CrossRefPubMed Luciani MG, Hutchins JR, Zheleva D, Hupp TR (2000) The C-terminal regulatory domain of p53 contains a functional docking site for cyclin A. J Mol Biol 300:503–518CrossRefPubMed
19.
go back to reference Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S (1992) Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 52:3674–3678PubMed Oda T, Tsuda H, Scarpa A, Sakamoto M, Hirohashi S (1992) Mutation pattern of the p53 gene as a diagnostic marker for multiple hepatocellular carcinoma. Cancer Res 52:3674–3678PubMed
20.
go back to reference Schneider J, Rubio MP, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS (1994) Identification of p53 mutations by means of single strand conformation polymorphism analysis in gynaecological tumours: comparison with the results of immunohistochemistry. Eur J Cancer 30:504–508CrossRef Schneider J, Rubio MP, Rodriguez-Escudero FJ, Seizinger BR, Castresana JS (1994) Identification of p53 mutations by means of single strand conformation polymorphism analysis in gynaecological tumours: comparison with the results of immunohistochemistry. Eur J Cancer 30:504–508CrossRef
22.
go back to reference Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149–1163PubMedCrossRef Sherr CJ, Roberts JM (1995) Inhibitors of mammalian G1 cyclin-dependent kinases. Genes Dev 9:1149–1163PubMedCrossRef
23.
go back to reference Shih HC, Shiozawa T, Kato K, Imai T, Miyamoto T, Uchikawa J, Nikaido T, Konishi I (2003) Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor suppressor gene products, Ki-67 and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as poor prognostic indicator. Human Pathol 34:471–478CrossRef Shih HC, Shiozawa T, Kato K, Imai T, Miyamoto T, Uchikawa J, Nikaido T, Konishi I (2003) Immunohistochemical expression of cyclins, cyclin-dependent kinases, tumor suppressor gene products, Ki-67 and sex steroid receptors in endometrial carcinoma: positive staining for cyclin A as poor prognostic indicator. Human Pathol 34:471–478CrossRef
24.
go back to reference Shiozawa T, Xin L, Nikaido T, Fujii S (1997) Immunohistochemical detection of cyclin A with reference to p53 expression in human endometrial endometrioid carcinoma. Int J Gynecol Pathol 16:348–353PubMedCrossRef Shiozawa T, Xin L, Nikaido T, Fujii S (1997) Immunohistochemical detection of cyclin A with reference to p53 expression in human endometrial endometrioid carcinoma. Int J Gynecol Pathol 16:348–353PubMedCrossRef
25.
go back to reference Shiozawa T, Nikaido T, Shimizu M, Zhai Y, Fujii S (1997) Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer 80:2250–2256CrossRefPubMed Shiozawa T, Nikaido T, Shimizu M, Zhai Y, Fujii S (1997) Immunohistochemical analysis of the expression of cdk4 and p16INK4 in human endometrioid-type endometrial carcinoma. Cancer 80:2250–2256CrossRefPubMed
26.
go back to reference Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ, Iacopetta BJ (1996) Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 74:562–567PubMed Soong R, Knowles S, Williams KE, Hammond IG, Wysocki SJ, Iacopetta BJ (1996) Overexpression of p53 protein is an independent prognostic indicator in human endometrial carcinoma. Br J Cancer 74:562–567PubMed
27.
go back to reference Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK, Iacopetta BJ (1996) Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Human Pathol 27:1050–1055CrossRef Soong R, Robbins PD, Dix BR, Grieu F, Lim B, Knowles S, Williams KE, Turbett GR, House AK, Iacopetta BJ (1996) Concordance between p53 protein overexpression and gene mutation in a large series of common human carcinomas. Human Pathol 27:1050–1055CrossRef
28.
go back to reference Soslow RA, Shen PU, Chung MH, Isacson C (1998) Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 17:129–134PubMed Soslow RA, Shen PU, Chung MH, Isacson C (1998) Distinctive p53 and mdm2 immunohistochemical expression profiles suggest different pathogenetic pathways in poorly differentiated endometrial carcinoma. Int J Gynecol Pathol 17:129–134PubMed
29.
go back to reference Yamamoto M, Yoshida M, Ono K, Fujita T, Ohtani-Fujita N, Sakai T, Nikaido T (1994) Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression. Exp Cell Res 210:94–101CrossRefPubMed Yamamoto M, Yoshida M, Ono K, Fujita T, Ohtani-Fujita N, Sakai T, Nikaido T (1994) Effect of tumor suppressors on cell cycle-regulatory genes: RB suppresses p34cdc2 expression and normal p53 suppresses cyclin A expression. Exp Cell Res 210:94–101CrossRefPubMed
30.
go back to reference Zhai YL, Nikaido T, Orii A, Horiuchi A, Toki T, Fujii S (1999) Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. Gynecol Oncol 75:453–459CrossRefPubMed Zhai YL, Nikaido T, Orii A, Horiuchi A, Toki T, Fujii S (1999) Frequent occurrence of loss of heterozygosity among tumor suppressor genes in uterine leiomyosarcoma. Gynecol Oncol 75:453–459CrossRefPubMed
Metadata
Title
Intratumoral heterogeneous expression of p53 correlates with p53 mutation, Ki-67, and cyclin A expression in endometrioid-type endometrial adenocarcinomas
Authors
Yu-Zhen Feng
Tanri Shiozawa
Akiko Horiuchi
Hsien-Chang Shih
Tsutomu Miyamoto
Hiroyasu Kashima
Akihisa Suzuki
Toshio Nikaido
Ikuo Konishi
Publication date
01-11-2005
Publisher
Springer-Verlag
Published in
Virchows Archiv / Issue 5/2005
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI
https://doi.org/10.1007/s00428-005-0029-9

Other articles of this Issue 5/2005

Virchows Archiv 5/2005 Go to the issue